Practical consensus recommendation on when to do BRCA testing

BRCA-mutation associated breast cancer and to future cancer risks and sensitivity to systemic therapies. Now that rapid genetic testing for BRCA1 and BRCA2 mutations is available, BRCA mutation status can be considered when making treatment and prevention decisions for BRCA testing, BRCA mutation ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, Purvish M., Wadhwa, J., Minhas, S., Gupta, A., Mittal, S., Ranjan, S., Mehta, P., Singh, R., Kataria, S. P., Salim, S., Ahmed, M., Aggarwal, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909285/
https://www.ncbi.nlm.nih.gov/pubmed/29721474
http://dx.doi.org/10.4103/sajc.sajc_112_18
Descripción
Sumario:BRCA-mutation associated breast cancer and to future cancer risks and sensitivity to systemic therapies. Now that rapid genetic testing for BRCA1 and BRCA2 mutations is available, BRCA mutation status can be considered when making treatment and prevention decisions for BRCA testing, BRCA mutation carriers with breast cancer. Expert group used data from published literature, practical experience, and opinion of a large group of academic oncologists, to arrive at practical consensus recommendations for use by the community oncologists.

Ejemplares similares